Natco Pharma Ltd.

Natco Pharma is currently trading at Rs. 348.00, up by 5.35 points or 1.56% from its previous closing of Rs. 342.65 on the BSE.

The scrip opened at Rs. 346.00 and has touched a high and low of Rs. 353.00 and Rs. 345.50 respectively. So far 12818 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 437.00 on 25-May-2012 and a 52 week low of Rs. 197.25 on 25-Nov-2011.

Last one week high and low of the scrip stood at Rs. 354.00 and Rs. 330.00 respectively. The current market cap of the company is Rs. 1092.05 crore.

The promoters holding in the company stood at 57.05% while Institutions and Non-Institutions held 17.37% and 25.58% respectively.   

Pharmaceutical company, Natco Pharma, has begun the sale of its first compulsorily licensed drug, which is the generic version of Bayer's Nexavar. The drug, which is used for the treatment of advanced kidney cancer, is priced at Rs 8,880 for a pack of 120 tablets. The company is expecting to add about Rs 15 crore revenue from this drug initially.

In a major blow, Natco Pharma recently lost a patent litigation against Israel's Teva Pharmaceutical Industries in the US over multiple sclerosis treatment drug - Copaxone.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets. The company began its operations in 1984 in Andhra Pradesh.